{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GI+Disorders&page=11",
    "query": {
      "condition": "GI Disorders",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 8147,
    "total_pages": 815,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GI+Disorders&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GI+Disorders&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T12:31:39.303Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04301986",
      "title": "Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Barrett Esophagus",
        "GERD"
      ],
      "interventions": [
        {
          "name": "Cytosponge",
          "type": "DEVICE"
        },
        {
          "name": "Transnasal Endoscopy (TNE)",
          "type": "DEVICE"
        },
        {
          "name": "Esophagogastroduodenoscopy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-08-11",
      "completion_date": "2022-05-10",
      "has_results": true,
      "last_update_posted_date": "2023-05-08",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04301986"
    },
    {
      "nct_id": "NCT03992469",
      "title": "Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "EBFAHF-2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 7,
      "start_date": "2023-02-15",
      "completion_date": "2026-02-02",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03992469"
    },
    {
      "nct_id": "NCT01482741",
      "title": "Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Colon Cancer",
        "Lung Cancer",
        "Neuroblastoma",
        "Testicular Cancer"
      ],
      "interventions": [
        {
          "name": "Focus Group Sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-11",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-25",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482741"
    },
    {
      "nct_id": "NCT04895722",
      "title": "Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab/Quavonlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab/Favezelimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab/Vibostolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-4830",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2021-06-25",
      "completion_date": "2026-08-06",
      "has_results": true,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 11,
      "location_summary": "Orange City, Florida • Athens, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895722"
    },
    {
      "nct_id": "NCT00132522",
      "title": "EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Colorectal Cancer",
        "Carcinoma, Non-small-cell Lung",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EMD 273066",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2005-05",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2013-10-25",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 4,
      "location_summary": "Durate, California • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Durate",
          "state": "California"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132522"
    },
    {
      "nct_id": "NCT03426345",
      "title": "Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroparesis",
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Relamorelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2018-02-16",
      "completion_date": "2020-07-16",
      "has_results": true,
      "last_update_posted_date": "2021-08-06",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 114,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 98 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03426345"
    },
    {
      "nct_id": "NCT00590239",
      "title": "Barrett's Esophagus Related Neoplasia (BERN) Project",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Barrett's Esophagus",
        "Neoplasms",
        "Gastroesophageal Reflux"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Midwest Biomedical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2007-05-15",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00590239"
    },
    {
      "nct_id": "NCT04660812",
      "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "AB680",
          "type": "DRUG"
        },
        {
          "name": "Etrumadenant",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "m-FOLFOX-6 regimen",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 227,
      "start_date": "2021-05-10",
      "completion_date": "2025-09-05",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04660812"
    },
    {
      "nct_id": "NCT03992079",
      "title": "A Multimodal Enhanced Recovery Program in Anorectal Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Disorders",
        "Anorectal Disorder",
        "Patient Satisfaction",
        "Pain, Postoperative",
        "Opioid Use",
        "Opioid Abuse",
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "ReCOVER Enhanced Recovery Protocol",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2019-06-20",
      "completion_date": "2020-05-21",
      "has_results": false,
      "last_update_posted_date": "2020-08-25",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03992079"
    },
    {
      "nct_id": "NCT00594854",
      "title": "Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Ulcer"
      ],
      "interventions": [
        {
          "name": "PN400 (VIMOVO)",
          "type": "DRUG"
        },
        {
          "name": "Diclofenac/Misoprostol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "POZEN",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-09",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2010-09-22",
      "last_synced_at": "2026-10-23T12:31:39.303Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594854"
    }
  ]
}